Grace Therapeutics, Inc. has announced its financial results for the third quarter of 2026, revealing a net loss of $2.1 million. This update is significant as it highlights the company's ongoing efforts to advance its drug GTx-104, which has completed a Phase 3 clinical trial. The results come at a crucial time as the company prepares to resubmit its New Drug Application (NDA) to the FDA.

Founded in Princeton, New Jersey, Grace Therapeutics operates in the pharmaceutical preparations sector (SIC 2834) and is listed on the Nasdaq under the ticker symbol GRCE. The company focuses on developing innovative therapies to address unmet medical needs, particularly in the area of acute subarachnoid hemorrhage (aSAH).

According to the recent SEC filing, Grace Therapeutics reported a net loss of $2.1 million, or $0.11 per share, for the three months ended September 30, 2026. This marks an increase in net loss compared to $0.9 million, or $0.06 per share, for the same period in 2025. The increase is attributed to a lack of favorable changes in the fair value of derivative warrant liabilities, which had positively impacted the previous year's results.

In the filing, CEO Prashant Kohli noted, “With no clinical safety or efficacy deficiencies identified in the U.S. Food and Drug Administration’s (FDA) Complete Response Letter (CRL), we continue to execute our plan to address the chemistry, manufacturing, and controls (CMC) and non-clinical data items, and are making progress toward resubmission of our New Drug Application (NDA) for GTx-104.” This statement underscores the company's commitment to overcoming regulatory hurdles and advancing its product toward market readiness.

The financial results also reflect an increase in research and development expenses, which rose to $0.9 million for the quarter. This increase is part of the company's strategy to support the manufacturing and regulatory work needed for GTx-104. The company has initiated a dual-source manufacturing strategy to mitigate potential issues with its current contract manufacturer and is actively working on non-clinical studies.

Grace Therapeutics' recent financing efforts, which included a $10 million private placement, are expected to extend the company's cash runway through the end of 2028. This funding will be crucial as the company navigates the complexities of the NDA resubmission process and continues to develop its product pipeline.

Looking ahead, Grace Therapeutics is expected to provide updates on its progress as it works toward achieving key milestones in its NDA resubmission process. The filing does not specify the exact timeline for the next steps, but the company remains optimistic about its future prospects.